CompletedNCT02699086
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- San FranciscoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 1, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 6
- Sponsor
- BioLite, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT02699086
- Official title
Show the full official title
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I
Get this study by email
Recruitment & locations
CompletedSan Francisco
Questions about this study
Who is behind this study?
The study sponsor is BioLite, Inc.
Did this study involve medication?
Yes. The study involved medication, including PDC-1421 Capsule.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)